Zyprexa

Matt Will, University of Indianapolis.

Lilly still had to fight The pharmaceutical giant offered to pay about $700 million to settle about 8,000 claims against In December, Lilly said stock earnings would be at the high end of its forecast.

Next up was Guidant, which issued a safety warning for its implantable devices.

Such problems put merger plans on life support.

At first, Johnson & Johnson planned to buy Guidant for $25 billion.

"They probably still do want Guidant, but they want to get it for less money,” said Greg Andrews, IBJ.

Another company, Boston Scientific, swooped in and made an offer.

That will be a business story next year.

Last month, the grocery chain Marsh said it was studying "strategic alternatives" after its latest financial report showed a big loss.

Marsh may put itself on the market because it's so hard to compete with bigger chains.

In January, ATA had high hopes of challenging its competition.

Then came job cuts and an end to flights out of Indianapolis, forcing ATA to step down as the dominant carrier at Indy to a very small player in the market.

This month, the government honored ATA for its service to the military.

The military gave Lawrence some good news with new jobs coming from the consolidation of defense...

Of the 866 patients who stopped treatment, 36% ( 315/866 ) did so because the treatment was felt not to be effective or because their symptoms worsened.

Only 12% of patients who stopped treatment early did so because of adverse events such as dizziness, fatigue, vomiting or weight gain.

Of the 315 patients who stopped because of poor response to treatment, 80% stopped because they themselves believed it wasn't effective.

Only 20% of the patients studied stopped taking medication based on a doctor's decision that the treatment wasn't effective.

" Discontinuation due to patient perception of poor response appeared to occur particularly early in the course of treatment," the authors write.

Liu-Seifert et al.

found that patients who experienced an early response to medication were 80% more likely to complete treatment.

The authors' findings suggest that early and effective symptom control, and discussing expectations of treatment, may help to ensure that people suffering from schizophrenia continue to take their medication.

Source: BioMed Central, 2005 XagenaMediciner2005 « Home Invia E-mail Web Xagena News Link • Biomedicine • Stem Therapy • Gene Medi...

More stories in Business • Monday misery mellows market • Music helps mobile revenues hit high note • States resist mergers into SAIL stable • Reliance stake shuffle in big deals • First quarter date for listing of Anil firms • Fast forward on automatic FDI • Currency comfort: Rupee rises to 45.05 • Gujarat Heavy Chem bags US firm • Risk service provider faces closure threat • Glenmark on African safari • Engineering duo in Buddha revival call • Nathu-La link • Power meet to seal pipeline project • Syrian spillover for OVL • High-end Syngenta laboratory in Bengal • Sundaram in German buyout • Sasken may take Rs 7cr hit Hosting from Canada Massage Therapy Training Schools Business Resources Health and Beauty Shopping and Gifts Web Advertising California Mortgage & Home Loans Here www.find- auto- insurance.us www.find- life- insurance.us Affordable Florida Vacation Rentals Company Registration Bollywood Ringtones Bollywood Wallpapers Hey Ya!